A review of melatonin in hepatic ischemia/reperfusion injury and clinical liver disease

Annals of Medicine

Volumn 46, Issue 7, 2014, Pages 503-511

  Li, Yue ^a   Yang, Yang ^a   Feng, Yingtong ^b,c   Yan, Juanjuan ^a   Fan, Chongxi ^b   Jiang, Shuai ^a   Qu, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c 97th Hospital of PLA   (China)

Author keywords

Antioxidant; Clinical liver disease; Hepatic ischemia reperfusion injury; Melatonin

Indexed keywords

HEME OXYGENASE 1; MELATONIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; ANTIOXIDANT;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEPATIC ENCEPHALOPATHY; HEPATITIS; HUMAN; INFORMATION; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER ISCHEMIA; LIVER PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; COMPLICATION; ENDOTHELIUM; LIVER; LIVER DISEASES; METABOLISM; MITOCHONDRION; VASCULARIZATION;

ANTIOXIDANTS; ENDOTHELIUM; HUMANS; LIVER; LIVER DISEASES; MELATONIN; MITOCHONDRIA; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84910004559     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.934275     Document Type: Review

References (98)

1. Yang Y, Duan W, Jin Z, Yi W, Yan J, Zhang S, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res. 2013;55:275-86.
2. Koh PO. Melatonin regulates the calcium-buffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J Pineal Res. 2012;53: 358-65.
3. Sezgin G, Oztürk G, Güney S, Sinanoʇlu O, Tunc¸demir M. Protective effect of melatonin and 1,25-dihydroxyvitamin D3 on renal ischemiareperfusion injury in rats. Ren Fail. 2013;35:374-9.
4. Sewerynek E, Reiter RJ, Melchiorri D, Ortiz GG, Lewinski A. Oxidative damage in the liver induced by ischemia/reperfusion: protection by melatonin. Hepatogastroenterology. 1996;43:898-905.
5. Hernández JA. [Effect of pretreatment with melatonin on the oxidative and inflammatory damage induced by hepatic ischemia/reperfusion in Zucker rats]. An R Acad Nac Med (Madr). 2011;128:391-415. [In Spanish]
6. Sener G, Tosun O, Sehirli AO, Kacmaz A, Arbak S, Ersoy Y, et al. Melatonin and N-acetylcysteine have beneficial effects during hepatic ischemia and reperfusion. Life Sci. 2003;72:2707-18.
7. Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res. 2011;50:403-11.
8. Liang R, Nickkholgh A, Hoffmann K, Kern M, Schneider H, Sobirey M, et al. Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res. 2009;46:8-14.
9. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol. 2005;165:139-49.
10. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 2000;7:444-58.
11. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1-9.
12. Ahmadiasl N, Banaei S, Alihemmati A, Baradaran B, Azimian E. The anti-inflammatory effect of erythropoietin and melatonin on renal ischemia reperfusion injury in male rats. Adv Pharm Bull. 2014;4:49-54.
13. Reiter RJ, Oh CS, Fujimori O. Melatonin its intracellular and genomic actions. Trends Endocrinol Metab. 1996;7:22-7.
14. Bharti VK, Srivastava RS, Kumar H, Bag S, Majumdar AC, Singh G, et al. Effects of melatonin and epiphyseal proteins on fluoride-induced adverse changes in antioxidant status of heart, liver, and kidney of rats. Adv Pharmacol Sci. 2014;2014:532969.
15. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. J Endocrinol. 1993;1:57-60.
16. Rodriguez AB, Nogales G, Marchena JM, Ortega E, Barriga C. Suppression of both basal and antigen-induced lipid peroxidation in ring dove heterophils by melatonin. Biochem Pharmacol. 1999;58:1301-6.
17. Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res. 2006;40:168-76.
18. Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci. 1994;55:PL455-60.
19. León J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res. 2005;38:1-9.
20. Espino J, Bejarano I, Paredes SD, González D, Barriga C, Reiter RJ, et al. Melatonin counteracts alterations in oxidative metabolism and cell viability induced by intracellular calcium overload in human leucocytes: changes with age. Basic Clin Pharmacol Toxicol. 2010;107:590-7.
21. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci. 2004;75:765-90.
22. Espino J, Bejarano I, Redondo PC, Rosado JA, Barriga C, Reiter RJ, et al. Melatonin reduces apoptosis induced by calcium signaling in human leukocytes: evidence for the involvement of mitochondria and bax activation. J Membr Biol. 2010;233:105-18.
23. Espino J, Bejarano I, Paredes SD, Barriga C, Rodríguez AB, Pariente JA. Protective effect of melatonin against human leukocyte apoptosis induced by intracellular calcium overload: relation with its antioxidant actions. J Pineal Res. 2011;51:195-206.
24. Javeshghani D, Barhoumi T, Idris-Khodja N, Paradis P, Schiffrin EL. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112-17.
25. Risbano MG, Gladwin MT. Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. Handb Exp Pharmacol. 2013;218:315-49.
26. Shah V, Kamath PS. Nitric oxide in liver transplantation: pathobiology and clinical implications. Liver Transpl. 2003;9:1-11.
27. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. J Pathol. 2003;199:8-17.
28. Marletta MA. N itric oxide synthase: aspects concerning structure and catalysis. Cell. 1994;78:927-30.
29. Dalkara T, Endres M, Moskowitz MA. Mechanisms of NO neurotoxicity. Prog Brain Res. 1998;118:231-9.
30. Strolin Benedetti M, Dostert P, Marrari P, Cini M. Effect of ageing on tissue levels of amino acids involved in the nitric oxide pathway in rat brain. J Neural Transm Gen Sect. 1993;94:21-30.
31. Soltis EE. Effect of age on blood pressure and membrane dependent vascular responses in the rat. Circ Res. 1987;61:889-97.
32. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol. 1995;269:H550-5.
33. Rodriguez-Reynoso S, Leal C, Portilla E, Olivares N, Muniz J. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumor necrosis factor-α and nitric oxide. J Surg Res. 2001;100:141-9.
34. Kilic U, Kilic E, Reiter RJ, Bassetti CL, Hermann DM. Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res. 2005;38:67-71.
35. Wang WZ, Fang XH, Stephenson LL, Baynosa RC, Khiabani KT, Zamboni WA. Microcirculatory effects of melatonin in rat skeletal muscle after prolonged ischemia. J Pineal Res. 2005;39:57-65.
36. Zhang WH, Li JY, Zhou Y. Melatonin abates liver ischemia/reperfusion injury by improving the balance between nitric oxide and endothelin. Hepatobiliary Pancreat Dis Int. 2006;5:574-9.
37. Zamzami N, Hirsch T, Dallaporta B, Petit PX, Kroemer G. Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. J Bioenerg Biomembr. 1997;29:185-93.
38. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999;341:233-49.
39. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46-54.
40. Frederiks WM, Vogels IM, Fronik GM. Plasma ornithine carbamyl transferase level as an indicator of ischaemic injury of rat liver. Cell Biochem Funct. 1984;2:217-20.
41. Okatani Y, Wakatsuki A, Reiter RJ, Enzan H, Miyahara Y. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol. 2003;469:145-52.
42. Kim SH, Lee SM. Cytoprotective effects of melatonin against necrosis and apoptosis induced by ischemia/reperfusion injury in rat liver. J Pineal Res. 2008;44:165-71.
43. Venegas C, García JA, Escames G, Ortiz F, López A, Doerrier C, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217-27.
44. Kireev R, Bitoun S, Cuesta S, Tejerina A, Ibarrola C, Moreno E, et al. Melatonin treatment protects liver of Zucker rats after ischemia/reperfusion by diminishing oxidative stress and apoptosis. Eur J Pharmacol. 2013;701:185-93.
45. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, et al. Mitochondrial adaptations to obesity related oxidant stress. Arch Biochem Biophys. 2000;378:259-68.
46. Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res. 2007;43:389-403.
47. Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J, Le Daux SP, et al. Alzheimer h protein mediated oxidative damage to mitochondrial DNA: prevention by melatonin. J Pineal Res. 1999;27:226-9.
48. Jiménez-Aranda A, Fernández-Vázquez G, Campos D, Tassi M, Velasco-Perez L, Tan DX, et al. Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. J Pineal Res. 2013;55:416-23.
49. Mattiasson G, Sullivan PG. The emerging functions of UCP2 in health, disease, and therapeutics. Antioxid Redox Signal. 2006;8:1-38.
50. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans. 2006;34:232-7.
51. Garcia JJ, Reiter RJ, Guerrero JM, Escames G, Yu BP, Oh CS, et al. Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett. 1997;408:297-300.
52. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517-54.
53. Zhu X, Fan WG, Li DP, Kung H, Lin MC. Heme oxygenase-1 system and gastrointestinal inflammation: a short review. World J Gastroenterol. 2011;17:4283-8.
54. Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, Lassman CR, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology. 2003;37:296-303.
55. Shen XD, Ke B, Zhai Y, Gao F, Busuttil RW, Cheng G, et al. Tolllike receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant. 2005;5:1793-800.
56. Kang JW, Lee SM. Melatonin inhibits type 1 interferon signaling of toll-like receptor 4 via heme oxygenase-1 induction in hepatic ischemia/reperfusion. J Pineal Res. 2012;53:67-76.
57. Tsuchihashi S, Zhai Y, Bo Q, Busuttil RW, Kupiec-Weglinski JW. Heme oxygenase-1 mediated cytoprotection against liver ischemia and reperfusion injury: inhibition of type-1 interferon signaling. Transplantation. 2007;83:1628-34.
58. O'neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol. 2003;3:396-403.
59. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury aft er murine liver ischemia-reperfusion. J Exp Med. 2005;201:1135-43.
60. Hertzog PJ, O'neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral. Trends Immunol. 2003;24:534-9.
61. Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008;205:2609-21.
62. Xiao X, Zhao P, Rodriguez-Pinto D, Qi D, Henegariu O, Alexopoulou L, et al. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol. 2009;183:3712-19.
63. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol. 2005;175:7661-8.
64. Huang SH, Cao XJ, Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophages. J Pineal Res. 2008;45:93-100.
65. Huang G, Shi LZ, Chi H. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine. 2009;48:161-9.
66. Johnson GL, Nakamura K. The c-Jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta. 2007;1773:1341-8.
67. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol. 2006;290:583-9.
68. Schemmer P, Schoonhoven R, Swenberg JA, Bunzendahl H, Thurman RG. Gentle in situ liver manipulation during organ harvest decreases survival aft er rat liver transplantation: role of Kupffer cells. Transplantation. 1998;65:1015-20.
69. Fan C, Li Q, Zhang Y, Liu X, Luo M, Abbott D, et al. IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation. J Clin Invest. 2004;113:746-55.
70. Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, et al. NK mediates hepatic ischemia reperfusion injury. J Hepatol. 2005;42:850-9.
71. Schemmer P, Nickkholgh A, Schneider H, Sobirey M, Weigand M, Koch M, et al. PORTAL: pilot study on the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection: a double-blind randomized placebo-controlled trial. BMC Surg. 2008;8:2.
72. Freitas I, Bertone V, Guarnaschelli C, Ferrigno A, Boncompagni E, Rizzo V, et al. In situ demonstration of improvement of liver mitochondria function by melatonin aft er cold ischemia. In Vivo. 2006;20:229-37.
73. Casillas-Ramírez A, Mosbah IB, Ramalho F, Roselló-Catafau J, Peralta C. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci. 2006;79:1881-94.
74. Pashkov AN, Popov SS, Semenikhina AV, Rakhmanova TI. Glutathione system and activity of NADPH-generating enzymes in the liver of intact rats and animals with toxic hepatitis receiving melatonin. Bull Exp Biol Med. 2005;139:565-8.
75. Popov SS, Shul'gin KK, Pashkov AN, Zoloedov VI, Shvedov GI. [Intensity of free radical oxidation and superoxide dismutase activity in patients with drug hepatitis in combination therapy with melaxen or epifamin]. Eksp Klin Gastroenterol. 2011;9:36-40. [In Russian]
76. Popov SS, Pashkov AN, Zoloedov VI, Shvedov GI. The use of melatonin in combined therapy of drug-induced hepatitis. Klin Med (Mosk). 2013;91:50-3.
77. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299-321.
78. Fourman LT, Robert Meyer B. Autoimmune hepatitis in association with ramelteon. J Clin Gastroenterol. 2013;47:651-4.
79. Cuesta S, Kireev R, Forman K, García C, Escames G, Ariznavarreta C, et al. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Exp Gerontol. 2010;45:950-6.
80. Zaouali MA, Boncompagni E, Reiter R J, Bejaoui M, Freitas I, Pantazi E, et al. AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail. J Pineal Res. 2013;55:65-78.
81. Cichoz-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol. 2010;61:577-80.
82. Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol. 2010;61:705-10.
83. Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol. 2012;63:35-40.
84. Celinski K, Konturek PC, Slomka M, Cichoz-Lach H, Gonciarz M, Bielanski W, et al. Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. J Pineal Res. 2009;46:408-14.
85. Montagnese S, Middleton B, Mani AR, Skene DJ, Morgan MY. On the origin and the consequences of circadian abnormalities in patients with cirrhosis. Am J Gastroenterol. 2010;105:1773-81.
86. Chojnacki C, Walecka-Kapica E, Klupiñska G, Wachowska-Kelly P, Żyliñska K, Winczyk K, et al. Serotonin and melatonin secretion and metabolism in patients with liver cirrhosis. Pol Arch Med Wewn. 2012;122:392-7.
87. Chojnacki C, Wachowska-Kelly P, Błasiak J, Reiter RJ, Chojnacki J. Melatonin secretion and metabolism in patients with hepatic encephalopathy. J Gastroenterol Hepatol. 2013;28:342-7.
88. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res. 2012;52:282-90.
89. Subramanian P, Mirunalini S, Dakshayani KB, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res. 2007;43:305-12.
90. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7:189-203.
91. Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis Int. 2002;1:183-6.
92. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;2245-7.
93. Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH, Jeong JW. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J Pineal Res. 2013;54:264-70.
94. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: metaanalysis. BMJ. 2006;332:385-93.
95. Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res. 2007;42:386-93.
96. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28-42.
97. Cheung RT, Tipoe GL, Tam S, Ma ES, Zou LY, Chan PS. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res. 2006;41:337-43.
98. Morera AL, Henry M, de La Varga M. Safety in melatonin use. Actas Esp Psiquiatr. 2001;29:334-37.